- Home
- HRMY vs HG Comparison
HRMY vs HG Comparison
Compare HRMY & HG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- HG
- Stock Information
- Founded
- HRMY 2017
- HG 2013
- Country
- HRMY United States
- HG Bermuda
- Employees
- HRMY N/A
- HG N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- HG
- Sector
- HRMY Health Care
- HG
- Exchange
- HRMY Nasdaq
- HG Nasdaq
- Market Cap
- HRMY 1.8B
- HG 2.2B
- IPO Year
- HRMY 2020
- HG 2023
- Fundamental
- Price
- HRMY $33.53
- HG $21.09
- Analyst Decision
- HRMY Strong Buy
- HG Buy
- Analyst Count
- HRMY 9
- HG 6
- Target Price
- HRMY $54.22
- HG $23.67
- AVG Volume (30 Days)
- HRMY 626.9K
- HG 498.5K
- Earning Date
- HRMY 08-05-2025
- HG 08-06-2025
- Dividend Yield
- HRMY N/A
- HG N/A
- EPS Growth
- HRMY 13.13
- HG N/A
- EPS
- HRMY 2.62
- HG 3.03
- Revenue
- HRMY $744,852,000.00
- HG $2,443,695,000.00
- Revenue This Year
- HRMY $20.10
- HG $14.39
- Revenue Next Year
- HRMY $18.01
- HG $11.69
- P/E Ratio
- HRMY $12.49
- HG $6.99
- Revenue Growth
- HRMY 20.62
- HG 27.70
- 52 Week Low
- HRMY $26.47
- HG $15.31
- 52 Week High
- HRMY $41.61
- HG $22.33
- Technical
- Relative Strength Index (RSI)
- HRMY 57.00
- HG 49.27
- Support Level
- HRMY $31.70
- HG $20.67
- Resistance Level
- HRMY $33.69
- HG $21.75
- Average True Range (ATR)
- HRMY 0.88
- HG 0.46
- MACD
- HRMY 0.11
- HG -0.06
- Stochastic Oscillator
- HRMY 93.44
- HG 31.11
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About HG Hamilton Insurance Group Ltd. Class B
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.